Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

MedDay completes patient enrolment in Phase III MD1003 trial

Photomicrograph of a demyelinating MS-Lesion. Credit: Marvin 101.

  • MedDay Pharmaceuticals

Go Top